SignalXSignalX

FOLD AMICUS THERAPEUTICS, INC.

Q3 2025 10-Q
Filed: Nov 4, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
AMICUS THERAPEUTICS, INC. Overview

AMICUS THERAPEUTICS, INC. (FOLD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • No new or changed risk factors disclosed since 2024 10-K
  • • Carried-forward regulatory risk: reliance on FDA approvals for product pipeline advancement
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$169M

▲ +19.5% YoY▲ +9.3% QoQ

Net Income

$17M

▲ +357.2% YoY▲ +170.9% QoQ

Gross Margin

88.5%

▼ -213bp YoY▼ -168bp QoQ

Operating Margin

20.3%

▲ +497bp YoY▲ +2639bp QoQ

Net Margin

10.2%

▲ +1499bp YoY▲ +2602bp QoQ

ROE

7.5%

Total Assets

$869M

EPS (Diluted)

$0.06

▲ +400.0% YoY▲ +175.0% QoQ

Operating Cash Flow

$36M

▲ +255.2% YoY▲ +234.4% QoQ

Source: XBRL data from AMICUS THERAPEUTICS, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on AMICUS THERAPEUTICS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.